Cargando…

Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE

SUMMARY: Early PINP changes correlate with 18-month lumbar spine BMD changes and the correlation was greater with abaloparatide versus teriparatide. The uncoupling index was similar between the two agents. INTRODUCTION: We evaluated the relationship between early PINP changes and subsequent changes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eastell, R., Mitlak, B. H., Wang, Y., Hu, M., Fitzpatrick, L. A., Black, D. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422956/ https://www.ncbi.nlm.nih.gov/pubmed/30635696 http://dx.doi.org/10.1007/s00198-018-04819-1

Ejemplares similares

Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice()
por: Arlt, Heike, et al.
Publicado: (2020)

Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling
por: Winzenrieth, R., et al.
Publicado: (2021)

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend
por: Deal, Chad L., et al.
Publicado: (2019)

Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study
por: Matsumoto, Toshio, et al.
Publicado: (2022)

SUN-385 Differential Effects of Abaloparatide and Teriparatide on Hip Cortical Volumetric BMD by DXA-Based 3d Modeling
por: Winzenrieth, Renaud, et al.
Publicado: (2020)

Teriparatide vs. Alendronate as a treatment for osteoporosis: Changes in biochemical markers of bone turnover, BMD and quality of life
por: Panico, Annalisa, et al.
Publicado: (2011)

Teriparatide and Abaloparatide Have a Similar Effect on Bone in Mice
por: Brent, Mikkel Bo, et al.
Publicado: (2021)

Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study
por: Cosman, F., et al.
Publicado: (2022)

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
por: Reginster, Jean-Yves, et al.
Publicado: (2018)

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide
por: Blumsohn, A., et al.
Publicado: (2010)

Abaloparatide Exerts Bone Anabolic Effects with Less Stimulation of Bone Resorption-Related Factors: A Comparison with Teriparatide
por: Makino, Akito, et al.
Publicado: (2018)

Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density
por: Miller, Paul D., et al.
Publicado: (2021)

Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women
por: Shiraki, M., et al.
Publicado: (2012)

Abaloparatide and the Spine: A Narrative Review
por: Thompson, Jeremy C, et al.
Publicado: (2020)

OR03-2 Different Effects of Abaloparatide and h-PTH(1-34) on Osteoclastogenesis and Bone Resorption
por: Arlt, Heike, et al.
Publicado: (2019)

Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis
por: Hong, Pan, et al.
Publicado: (2023)

Abaloparatide versus teriparatide: a head to head comparison of effects on fracture healing in mouse models
por: Bernhardsson, Magnus, et al.
Publicado: (2018)

Comparative study in estrogen-depleted mice identifies skeletal and osteocyte transcriptomic responses to abaloparatide and teriparatide
por: Lv, Zhengtao, et al.
Publicado: (2023)

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis
por: Dempster, David W, et al.
Publicado: (2021)

OR03-1 The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
por: Lane, Nancy, et al.
Publicado: (2019)

Concordane of OSTA and lumbar spine BMD by DXA in identifying risk of osteoporosis
por: Lu, ChunYan, et al.
Publicado: (2006)

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
por: Greenspan, Susan L., et al.
Publicado: (2020)

The fracture predictive ability of lumbar spine BMD and TBS as calculated based on different combinations of the lumbar spine vertebrae
por: Shevroja, Enisa, et al.
Publicado: (2022)

The Antioxidant Enzyme GPX1 Gene Polymorphisms Are Associated with Low BMD and Increased Bone Turnover Markers
por: Mlakar, Simona Jurkovic, et al.
Publicado: (2010)

Response to teriparatide in Chinese patients with established osteoporosis: osteocalcin and lumbar spine bone-mineral density changes from teriparatide Phase III study
por: Lu, Chunyan, et al.
Publicado: (2017)

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Relationship Among Panoramic Radiography Findings, Biochemical Markers of Bone Turnover and Hip BMD in the Diagnosis of Postmenopausal Osteoporosis
por: Johari Khatoonabad, M., et al.
Publicado: (2011)

Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β‐arrestin recruitment than teriparatide
por: Sahbani, Karim, et al.
Publicado: (2019)

Bone Turnover Markers: Basic Biology to Clinical Applications
por: Schini, Marian, et al.
Publicado: (2022)

Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
por: Dhaliwal, Ruban, et al.
Publicado: (2020)

Associations between Body Composition, Hormonal and Lifestyle Factors, Bone Turnover, and BMD
por: Gourlay, Margaret L., et al.
Publicado: (2014)

Comparable Initial Engagement of Intracellular Signaling Pathways by Parathyroid Hormone Receptor Ligands Teriparatide, Abaloparatide, and Long‐Acting PTH
por: Sato, Tadatoshi, et al.
Publicado: (2021)

Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
por: Dhaliwal, Ruban, et al.
Publicado: (2020)

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
por: Bone, Henry G, et al.
Publicado: (2018)

Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis
por: Sugimoto, T., et al.
Publicado: (2013)

Low Bone Turnover and Low BMD in Down Syndrome: Effect of Intermittent PTH Treatment
por: Fowler, Tristan W., et al.
Publicado: (2012)

Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial
por: Cosman, Felicia, et al.
Publicado: (2020)

Characteristics of Bone Turnover in the Long Bone Metaphysis Fractured Patients with Normal or Low Bone Mineral Density (BMD)
por: Wölfl, Christoph, et al.
Publicado: (2014)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis
por: Imel, E.A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cp2cssm3cqko5mrrc9u9na3o9o